We don’t support this browser anymore.
This means our website may not look and work as you would expect. Read more about browsers and how to update them here.

Skip to main content
  • Register
  • Help
  • Contact us

Aptose Biosciences Inc (APS) Ord Shares NPV

Sell:1.69 CAD Buy:1.73 CAD Change: 0.01 CAD (0.60%)
Market closed |  Prices as at close on 14 January 2022 | Switch to live prices |
Sell:1.69 CAD
Buy:1.73 CAD
Change: 0.01 CAD (0.60%)
Market closed |  Prices as at close on 14 January 2022 | Switch to live prices |
Sell:1.69 CAD
Buy:1.73 CAD
Change: 0.01 CAD (0.60%)
Market closed |  Prices as at close on 14 January 2022 | Switch to live prices |
The selling price currently displayed is higher than the buying price. This can occur temporarily for a variety of reasons; shortly before the market opens, after the market closes or because of extraordinary price volatility during the trading day.

Business summary

Aptose Biosciences Inc. is a clinical-stage biotechnology company that is focused on discovering and developing personalized therapies addressing unmet medical needs in oncology. The Company has two clinical-stage investigational products for hematologic malignancies: luxeptinib and APTO-253. The luxeptinib is a mutation agnostic Bruton’s tyrosine kinase (BTK) kinase inhibitor, which is in a Phase I a/b trial in patients with refractory B cell malignancies, including chronic lymphocytic leukemia (CLL), small lymphocytic lymphoma (SLL) and non-Hodgkin lymphoma (NHL), who have failed or are intolerant to standard therapies and is in a separate Phase I a/b trial in patients with refractory acute myeloid leukemia (AML). Its APTO-253 is the clinical stage agent that directly targets the Master Regulator of Cell Cycle Entry and Proliferative Metabolism (MYC) oncogene and suppresses its expression, which is in a Phase I a/b clinical trial for the treatment of patients with relapsed.

Contact details

Address:
251 Consumers Rd Suite 1105
NORTH YORK
M2J 4R3
Canada
Telephone:
+1 (647) 4799828
Website:
https://aptose.com/

Important dates

Future events
There are no future events available.
Past events
There are no past events available.

General stock information

Short code:
APS
ISIN:
CA03835T2002
Market cap:
153.06 million CAD
Shares in issue:
88.95 million
Sector:
Biotechnology
Exchange:
Toronto Stock Exchange
Country:
Canada
Currency:
Canadian dollars
Indices:
n/a

Key personnel

  • William Rice
    Chairman of the Board, President, Chief Executive Officer
  • Jotin Marango
    Chief Financial Officer, Chief Accounting Officer, Chief Business Officer
  • Rafael Bejar
    Senior Vice President, Chief Medical Officer
  • Janet Clennett
    Vice President - Finance
  • Roger Davies
    Vice President - Operations
  • Robert Killion
    Vice President - CMC
  • George Melko
    Vice President - Regulatory Affairs

Data policy - All information should be used for indicative purposes only. You should independently check data before making any investment decision. HL cannot guarantee that the data is accurate or complete, and accepts no responsibility for how it may be used. Business summary, contact details and key personnel provided by Thomson Reuters. Important dates provided by Digital Look Ltd. General stock information provided by Reuters.

Share

The London Stock Exchange does not disclose whether a trade is a buy or a sell so this data is estimated based on the trade price received and the LSE-quoted mid-price at the point the trade is placed. It should only be considered an indication and not a recommendation.

Trades priced above the mid-price at the time the trade is placed are labelled as a buy; those priced below the mid-price are sells; and those priced close to the mid-price or declared late are labelled 'N/A'.